2014
Immunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Educational MaterialsConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules
2007
Cutaneous Perspectives on Adaptive Immunity
Girardi M. Cutaneous Perspectives on Adaptive Immunity. Clinical Reviews In Allergy & Immunology 2007, 33: 4-14. PMID: 18094943, DOI: 10.1007/s12016-007-0040-9.Peer-Reviewed Original ResearchConceptsAntigen-specific responsesAdaptive immunityAdaptive immune systemDendritic cellsEffector cellsImmunologic memoryTumor immunosurveillanceInflammatory diseasesT cellsImmune responseImmune systemMajor subsetEndothelial cellsSkinMicrobial defenseImmunocytesImmunityEfficient surveillanceCellsResponseImmunosurveillanceChemokinesCytokinesLymphocytesDamaging agents
2005
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature Immunology 2005, 6: 928-937. PMID: 16116470, DOI: 10.1038/ni1239.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsCarcinomaCell Line, TumorDisease SusceptibilityDown-RegulationFemaleImmunologic SurveillanceKiller Cells, NaturalLigandsMaleMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicNK Cell Lectin-Like Receptor Subfamily KPapillomaReceptors, ImmunologicReceptors, Natural Killer CellSkin NeoplasmsT-LymphocytesTetradecanoylphorbol AcetateTumor BurdenConceptsNKG2D downregulationNK cell-mediated cytotoxicityNatural killer cellsCell-mediated cytotoxicityInnate immune activationT cell defectsNKG2D engagementNatural cytotoxicityKiller cellsImmune activationReceptor NKG2DTumor immunosurveillanceCutaneous carcinogenesisTumor surveillanceT cellsReversible defectsRAE-1Normal epitheliumLigand expressionTumor resistanceCell defectsSustained expressionNKG2DImmunosurveillanceDownregulation
2003
γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity. Journal Of Experimental Medicine 2003, 198: 433-442. PMID: 12900519, PMCID: PMC2194096, DOI: 10.1084/jem.20030584.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsImmunity, CellularInterferon-gammaInterleukin-12Lymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutNeoplasm TransplantationNeoplasms, ExperimentalReceptors, Antigen, T-Cell, alpha-betaReceptors, Antigen, T-Cell, gamma-deltaT-Lymphocyte SubsetsTransplantation ChimeraTumor Cells, CulturedConceptsGammadelta T cellsAlphabeta T cellsT cellsTumor immunityIFN-gammaHigh incidenceGammadelta T cell-deficient miceImpaired IFN-gamma productionT cell-deficient miceTumor developmentCell-deficient miceBone marrow chimerasΓδ T cellsIFN-gamma productionSite of tumorT cell repertoireWild-type miceChemical carcinogen methylcholanthreneMelanoma cell line B16B16 melanoma cellsTumor lysateCarcinogen methylcholanthreneTumor immunosurveillanceInterferon γSuch mice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply